Geographic Atrophy

Inflammasome Therapeutics announced positive phase 2 results achieved by kamuvudine-8 (K8), its investigational drug, for geographic atrophy (GA) and a good safety signal over the 6-month period of evaluation. The company also reported significantly slower GA progression and a visual acuity advantage.

The randomized, double-masked, 3-arm trial did not achieve its primary endpoint of replicating the visual function improvements observed in a smaller phase 1/2a study.

The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.

Three real-world cases illustrate strategies to identify and manage GA across a range of scenarios, from coexisting wet age-related macular degeneration to functionally monocular patients.

In a preference study, Csaky and colleagues found that lesion growth rate reduction was the primary driver of GA treatment decisions among US retina specialists, with greater risk tolerance for foveal-threatening lesions.

Sunil S. Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mechanism targeting harmful gut bacteria and retinal inflammation, what the phase 2 drusen volume and GA growth rate data reveal about the therapy's potential, and what a phase 3 program must address to bring an oral AMD treatment to patients without options.

Biogen buys Apellis, taking over Syfovre for geographic atrophy—what it means for GA care, trial data, safety signals, and future formulations.

Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.

Oral QA102 shows imaging signals slowing drusen and GA progression in intermediate dry AMD at ARVO 2026, despite missing its primary end point.

Biogen’s $5.6B Apellis deal boosts GA and renal complement therapies, spotlighting SYFOVRE benefits, safety signals, and future access.

The Opti-GAIN study from Complement Therapeutics is assessing the safety, tolerability, and preliminary efficacy in GA secondary to age-related macular degeneration (AMD) of CTx001.

Q1 2026 eye-care roundup: first dual-agent presbyopia drop, new EDOF IOL, wet AMD phase 3 win, and gene-therapy advances.

Phase 2 ArMaDa data show statistically significant 31% reduction in GA lesion growth with OCU410 at 12 months, with a favorable safety profile supporting phase 3 development.

The trial, sponsored by ONL Therapeutics, aims to enroll approximately 324 patients across sites in Europe, the United States, and Canada.

University of Utah data show US ophthalmic drug and eye drop shortages last longer and occur more often, affecting local and systemic medications equally.

Three real-world GA cases reveal why early imaging-guided treatment matters, how fast vision can decline, and how to manage CNV risk with anti-VEGF.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Experts debate real-world retina cases—mystery vitreous hemorrhage, floater vitrectomy, buckle comeback, PDR laser vs anti-VEGF, GA timing.

The results of a multicenter controlled clinical trial showed that the device resulted in “a significant improvement in visual acuity (VA) from baseline to month 12.

The deal will see MeiraGTx assume development rights to ZipBio’s experimental therapies targeting the complement pathway in geographic atrophy (GA).

MTII tracking in geographic atrophy reveals central macula preservation and predicts vision loss better than lesion area, shaping future trial endpoints.

From artificial intelligence and IOL innovation to biosimilars, geographic atrophy, and postoperative eye protection, Joshua Mali, MD, FASRS, shares what he believes will define ophthalmology in the year ahead.

Learn how multimodal imaging and complement inhibitors reshape geographic atrophy care, guiding early treatment, CNV monitoring, and AI-driven follow-up.

A total of 38 patients were included in the study. All underwent implantation of the PRIMAretinal prosthetic chip with the goal of restoring vision.